Records containing: Myelodysplastic Syndromes
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2024-08-22An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
-
CLINICAL_TRIALS study record update · 2024-08-21A Feasibility Study Evaluating Connected Bikes as a Means of Adapted Physical Activity in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2024-08-13A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)
-
CLINICAL_TRIALS study record update · 2024-08-05A Study of VA Combined With PD-1 Inhibitor in the Treatment of Relapsed and Refractory AML and High-risk MDS
-
CLINICAL_TRIALS study record update · 2024-08-02A Phase 1b Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX727 (Cedazuridine and Decitabine) in Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2024-08-02A Phase I/IIa Open-label Study to Assess the Safety, Tolerability and Preliminary Efficacy of AT9283, a Small Molecule Inhibitor of Aurora Kinases, in Patients With Refractory Hematological Malignancies
-
CLINICAL_TRIALS study record update · 2024-08-01Randomized Trial of Sorafenib Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplantation Bendamustine and Cyclophosphamide
-
CLINICAL_TRIALS study record update · 2024-07-31Randomized Study of Vitamin A and D Prophylaxis Before Allogeneic Related and Unrelated Hematopoietic Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2024-07-31An Adaptive Phase 2 Study of Tipifarnib in Subjects With Myelodysplastic Syndromes
-
CLINICAL_TRIALS study record update · 2024-07-29An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03
-
CLINICAL_TRIALS study record update · 2024-07-12A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA)
-
CLINICAL_TRIALS study record update · 2024-07-10Immunophenotyping of Blood Cells in the Diagnosis Work-up of Myelodysplastic Syndromes
-
CLINICAL_TRIALS study record update · 2024-07-01A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), and Acute Myeloid Leukemia (AML)
-
CLINICAL_TRIALS study record update · 2024-06-27Randomized Trial of Benadamustine Versus Ruxolitinib With Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation
-
CLINICAL_TRIALS study record update · 2024-06-26A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alpha for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Due to Myelodysplastic Syndrome (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
-
CLINICAL_TRIALS study record update · 2024-06-24Expanded Access Treatment With Imetelstat For Adult Participants With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Are Transfusion-Dependent And Have Failed to Respond or Have Lost Response or Are Ineligible For Erythropoiesis-Stimulating Agents (ESAs)
-
CLINICAL_TRIALS study record update · 2024-06-21PTQA: A New Paradigm of Transfusion Decision Support for Patients With MDS
-
CLINICAL_TRIALS study record update · 2024-06-17An Open-label, Multicenter, Phase 1 Study to Evaluate Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
-
CLINICAL_TRIALS study record update · 2024-06-14A Phase II Trial of Venetoclax-Enhanced Reduced Intensity HLA-Mismatched Allogeneic Transplant for Ultra-High-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
-
CLINICAL_TRIALS study record update · 2024-06-12Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome, Including Long-term Safety Follow-up
-
CLINICAL_TRIALS study record update · 2024-06-11A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes
-
CLINICAL_TRIALS study record update · 2024-05-28Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486
-
CLINICAL_TRIALS study record update · 2024-05-21Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML
-
CLINICAL_TRIALS study record update · 2024-05-20Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes
-
CLINICAL_TRIALS study record update · 2024-05-16A Phase I/II Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias or Myelodysplastic Syndromes